A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

Item
http://www.wikidata.org/entity/Q33418091
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Macrophages are critical effectors of antibody therapies for cancerSingle-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.Recent advances in therapy of chronic lymphocytic leukaemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
P2860

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

Item
http://www.wikidata.org/entity/Q33418091
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@ast
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@en
type
label
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@ast
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@en
prefLabel
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@ast
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
A phase 1 trial of the Fc-engi ...... inary efficacy in relapsed CLL
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2014-08-593269
P407
P433
P478
P50
P577
P5875
P698
P921
P932